{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:19:52Z","timestamp":1790630392972,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40261-025-01475-2","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T07:42:37Z","timestamp":1756626157000},"page":"909-913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Mitomycin Intravesical Solution: First Approval"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7645","authenticated-orcid":false,"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"1475_CR1","unstructured":"World Bladder Cancer Patient Coalition. GLOBOCAN 2022: bladder cancer 9th most common worldwide. 2024. https:\/\/worldbladdercancer.org\/. Accessed 14 July 2025."},{"key":"1475_CR2","doi-asserted-by":"publisher","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, Henne C, Mariappan P, et al. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124.","journal-title":"Front Oncol"},{"issue":"2","key":"1475_CR3","first-page":"43","volume":"22","author":"RS Matulewicz","year":"2020","unstructured":"Matulewicz RS, Steinberg GD. Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol. 2020;22(2):43\u201351.","journal-title":"Rev Urol"},{"key":"1475_CR4","unstructured":"American Cancer Society. Intravesical therapy for bladder cancer. 2025. https:\/\/www.cancer.org\/. Accessed 14 Jul 2025."},{"key":"1475_CR5","unstructured":"American Urological Association. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline. 2025. https:\/\/www.auanet.org\/. Accessed 18 Jul 2025."},{"issue":"2","key":"1475_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JU.0000000000004296","volume":"213","author":"SM Prasad","year":"2025","unstructured":"Prasad SM, Shishkov D, Mihaylov NV, et al. Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: a single-arm, open-label, phase 3 trial (ENVISION). J Urol. 2025;213(2):205\u201316.","journal-title":"J Urol"},{"key":"1475_CR7","unstructured":"UroGen Pharma Inc. Mitomycin intravesical solution: US prescribing information. 2025. https:\/\/www.urogen.com\/. Accessed 17 Jul 2025."},{"key":"1475_CR8","unstructured":"UroGen Pharma Inc. RTGel\u00ae technology. 2024. https:\/\/www.urogen.com\/. Accessed 14 Jul 2025."},{"key":"1475_CR9","unstructured":"UroGen Pharma Inc. US FDA approves UroGen\u2019s ZUSDURI\u2122 (mitomycin) for intravesical solution as the first and only medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) [media release]. 12 Jun 2025. https:\/\/investors.urogen.com\/."},{"key":"1475_CR10","unstructured":"US Food & Drug Administration. FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer [media release]. 12 Jun 2025. https:\/\/www.fda.gov\/."},{"key":"1475_CR11","unstructured":"US Food & Drug Administration. FDA approves mitomycin for low-grade upper tract urothelial cancer [media release]. 15 April 2020. https:\/\/www.fda.gov\/."},{"key":"1475_CR12","unstructured":"UroGen Pharma Inc. Mitomycin for pyelocalyceal solution. 2024. https:\/\/www.jelmyto.com\/. Accessed 14 Jul 2025."},{"key":"1475_CR13","doi-asserted-by":"crossref","unstructured":"Prasad SM, Mihaylov NV, Khuskivadze A, et al. Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial [abstract no. 4598]. J Clin Oncol. 2025;43(16 Suppl).","DOI":"10.1200\/JCO.2025.43.16_suppl.4598"},{"issue":"4","key":"1475_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JU.0000000000003645","volume":"210","author":"SM Prasad","year":"2023","unstructured":"Prasad SM, Huang WC, Shore ND, et al. Treatment of low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102 \u00b1 transurethral resection of bladder tumor compared to transurethral resection of bladder tumor monotherapy: a randomized, controlled, phase 3 trial (ATLAS). J Urol. 2023;210(4):619\u201329.","journal-title":"J Urol"},{"issue":"1","key":"1475_CR15","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/JU.0000000000002186","volume":"207","author":"KK Chevli","year":"2022","unstructured":"Chevli KK, Shore ND, Trainer A, et al. Primary chemoablation of low-grade intermediate-risk nonmuscle-invasive bladder cancer using UGN-102, a mitomycin-containing reverse thermal gel (Optima II): a phase 2b, open-label, single-arm trial. J Urol. 2022;207(1):61\u20139.","journal-title":"J Urol"},{"key":"1475_CR16","doi-asserted-by":"crossref","unstructured":"Shore N, Chevli K, Trainer A, et al. Treatment of low-grade intermediate-risk non-muscle invasive bladder cancer with UGN-102: long-term outcomes of the OPTIMA II study [abstract no. MP15-05]. J Urol. 2025;213(5 Suppl):e497.","DOI":"10.1097\/01.JU.0001109876.32161.cb.05"},{"key":"1475_CR17","doi-asserted-by":"crossref","unstructured":"Morris D, Kramolowsky EV, Bivins VM, et al. Home instillation of UGN-102 for primary chemoablation of recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer: a single-arm, open-label, phase 3B trial [abstract no. 124]. In: Urologic Oncology: Seminars and Original Investigations. 2025.","DOI":"10.1016\/j.urolonc.2024.12.127"}],"updated-by":[{"DOI":"10.1007\/s40261-025-01491-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01475-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01475-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01475-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:57:28Z","timestamp":1760774248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01475-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1475"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01475-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-025-01491-2","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"18 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to a retrospective Open Access order.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-025-01491-2","URL":"https:\/\/doi.org\/10.1007\/s40261-025-01491-2","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}